Drug

Selegiline

In clinical development

ClassMonoamine oxidase B inhibitorEmerging researchLate-stage development

Also known as Anipryl, Atapryl, Carbex, Eldepryl+7 more

Anipryl, Atapryl, Carbex, Eldepryl, Emsam, L-Deprenalin, Zelapar, (-)-selegiline, Selegilina, Selegiline Hydrochloride, Selegilinum.

RxNorm9639 ChEMBLCHEMBL972 ATCN04BD01UNII2K1V7GP655

Research papers

MAOB

Primary target

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

Clinical trial2025-02-01Primary completion · ClinicalTrials.gov

A Multi-center, Open-Label Study to Evaluate the Efficacy and Safety of Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease

Clinical trial2021-04-30Completed · ClinicalTrials.gov

The Effects of a Single Dose on Reward and Emotional Processing in Healthy Volunteers

Clinical trial2020-09-10Primary completion · ClinicalTrials.gov

An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.

Clinical trial2018-12-01Primary completion · ClinicalTrials.gov

Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence

Clinical trial2017-01-12Completed · ClinicalTrials.gov

Infusion Laboratory: Protocol 1 - Selegeline

Clinical trial2017-01-12Completed · ClinicalTrials.gov

Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline

Clinical trial2017-01-11Status unknown · ClinicalTrials.gov

Selegiline Patch for Treatment of Nicotine Dependence

Clinical trial2016-08-10Results posted · ClinicalTrials.gov

Usefulness of Selegiline for Smoking Cessation

Clinical trial2015-03-31Results posted · ClinicalTrials.gov

A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety

Clinical trial2015-03-01Completed · ClinicalTrials.gov

Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy.

Research2010-09-01Addiction (Abingdon, England)

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Research1997-04-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Selegiline

Aliases & brands

AniprylAtaprylCarbexEldeprylEmsamL-DeprenalinZelapar(-)-selegilineSelegilinaSelegiline HydrochlorideSelegilinum

RxNorm CUI

9639

ChEMBL ID

CHEMBL972

ATC codes

N04BD01

UNII

2K1V7GP655

Primary mechanism

Monoamine oxidase B inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Amine oxidase [flavin-containing] B

MAOB · P27338

INHIBITORMonoamine oxidase B inhibitor

Clinical trials

19 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2021

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 19

Early Phase 11Phase 12Phase 210Phase 32Phase 42Phase N / A2

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Multi-center, Open-Label Study to Evaluate the Efficacy and Safety of Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease

CompletedPH IVSecond Affiliated Hospital of Soochow Universityn=1412021

An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.

Unknown statusPH IVUniversity of South Floridan=102019

A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety

CompletedPH IIIMood and Anxiety Research, Incn=302015

Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence

CompletedPH IIINational Institute on Drug Abuse (NIDA)n=2692002

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Multi-center, Open-Label Study to Evaluate the Efficacy and Safety of Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease

CompletedPH IVSecond Affiliated Hospital of Soochow Universityn=1412021

A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety

CompletedPH IIIMood and Anxiety Research, Incn=302015

Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior

CompletedPH IIMidwest Biomedical Research Foundationn=122013

Usefulness of Selegiline for Smoking Cessation

CompletedPH IIYale Universityn=1012012

Selegiline Patch for Treatment of Nicotine Dependence

CompletedPH IIStanford Universityn=2432011

Efficacy of Selegiline Augmentation of Antipsychotic Medication to Treat Negative Symptoms in Inpatients With Chronic Schizophrenia

CompletedPH ITabriz Universityn=702007

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

19972010

Most influential

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

The New England journal of medicine · 1997 · 1,344 cites

Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy.

Addiction (Abingdon, England) · 2010 · 26 cites